Abivax
ABVX
30 hedge funds and large institutions have $228M invested in Abivax in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
33.83% more ownership
Funds ownership: 0% → 33.83% (+34%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$43.8M |
| 2 |
Blackstone Inc
New York
|
+$24.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$21.7M |
| 4 |
CC
Commodore Capital
New York
|
+$19.3M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15.8M |
Top Sellers
ABVX Hedge Fund Activity: Q4 2023 in Review
30 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q4 2023, worth a combined $228M.
Buyers outnumbered sellers: 30 funds opened new ABVX positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $43.8M.
- 30 institutional investors held Abivax (ABVX) as of Q4 2023, up from 0 in Q3 2023.
- Funds reported $228M of Abivax stock for Q4 2023.
- 30 funds opened new Abivax positions in Q4 2023 and 0 closed out, a net change of +30 holders.
- The largest Abivax buyer in Q4 2023 was Deep Track Capital, an estimated $43.8M added.
Based on aggregated 13F filings for Q4 2023.